Caris Life Sciences, Inc. (CAI) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — CAI

Balance Sheet

(in billions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025
Cash & Equivalents	--	0.82	0.75	0.72
Short-term Investments	0.10	0.00	0.00	0.00
Accounts Receivable	0.12	0.09	0.03	0.05
Total Current Assets	1.06	1.01	0.85	0.83
Property, Plant & Equipment	0.10	0.08	0.06	0.06
Goodwill	0.02	0.02	0.02	0.02
Total Non-current Assets*	0.17	0.15	0.13	0.12
Total Assets	1.23	1.16	0.98	0.96
Accounts Payable	0.09	0.07	0.03	0.03
Total Current Liabilities	0.19	0.14	0.09	0.09
Long-term Debt	0.39	0.38	0.38	0.37
Total Non-current Liabilities*	0.45	0.43	0.42	0.41
Total Liabilities	0.64	0.57	0.51	0.50
Retained Earnings	(2.55)	(2.55)	(2.63)	(2.66)
Total Stockholder Equity	0.59	0.59	0.48	0.45

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025
Total Revenue	263.71	216.17	292.89	216.83	181.40
Research & Development	32.36	31.32	31.85	21.62	25.05
Selling, General & Admin	66.55	59.71	56.51	51.97	64.37
Operating Income	26.93	5.28	88.41	32.64	(17.99)
Pretax Income	(0.61)	(0.64)	81.96	24.33	(71.79)
Tax Provision	0.02	(0.13)	0.00	0.00	0.00
Net Income	(0.64)	(0.51)	81.96	24.33	(71.79)
Basic EPS	0.00	0.00	1.61	0.09	(7.97)
Diluted EPS	0.00	0.00	1.61	0.08	(7.97)

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025
Operating Cash Flow	28.48	32.88	44.78	62.43	(24.05)
Capital Expenditures	32.42	10.34	5.09	7.10	4.08
Free Cash Flow*	(3.94)	22.53	39.69	55.33	(28.12)
Investing Cash Flow	(122.19)	(10.34)	(5.09)	(7.09)	(4.07)
Financing Cash Flow	(36.90)	0.82	3.40	(21.10)	682.69

* Derived from reported values